Summit Therapeutics (SMMT) Current Assets (2018 - 2026)
Summit Therapeutics' (SMMT) quarterly Current Assets came in at $720.6 million in Q2 2026, up 133.02% YoY from $309.2 million in Q2 2025, and up 16.86% on a QoQ basis from $616.6 million in Q1 2026.
Summit Therapeutics (SMMT) Current Assets (2018 - 2026) Analysis & Trends
Summit Therapeutics (SMMT) has 9 years of Current Assets data on file, last reported at $720.6 million in Q2 2026.
- Quarterly Current Assets rose 133.02% year-over-year to $720.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $720.6 million (up 133.02% YoY) and the FY2025 annual result came in at $720.3 million, up 69.98% from the prior year.
- Current Assets climbed to $720.6 million in Q2 2026, from $616.6 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $720.6 million in Q2 2026 to a low of $79.4 million in Q2 2022.
- A 5-year average of $346.3 million and a median of $278.6 million in 2023 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2022 — Current Assets surged 574.85% — and 2023, when it plunged 71.11%.
- Tracing SMMT's Current Assets over 5 years: stood at $656.7 million in 2022, then sank by 71.11% to $189.7 million in 2023, then surged by 123.36% to $423.8 million in 2024, then surged by 69.98% to $720.3 million in 2025, then rose by 0.04% to $720.6 million in 2026.
- The last three Current Assets figures came in at $720.6 million (Q2 2026), $616.6 million (Q1 2026), and $720.3 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Summit Therapeutics | 10.59 Bn | 9.90 Bn | - | 720.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 720.58 Mn |
| Mar 31, 2026 | 616.60 Mn |
| Dec 31, 2025 | 720.30 Mn |
| Sep 30, 2025 | 246.47 Mn |
| Jun 30, 2025 | 309.24 Mn |
| Mar 31, 2025 | 370.75 Mn |
| Dec 31, 2024 | 423.75 Mn |
| Sep 30, 2024 | 490.29 Mn |
| Jun 30, 2024 | 328.79 Mn |
| Mar 31, 2024 | 163.27 Mn |
| Dec 31, 2023 | 189.71 Mn |
| Sep 30, 2023 | 204.95 Mn |
| Jun 30, 2023 | 227.50 Mn |
| Mar 31, 2023 | 248.03 Mn |
| Dec 31, 2022 | 656.71 Mn |
| Sep 30, 2022 | 137.12 Mn |
| Jun 30, 2022 | 79.40 Mn |
| Mar 31, 2022 | 99.44 Mn |
| Dec 31, 2021 | 97.31 Mn |
| Sep 30, 2021 | 102.21 Mn |